Chondrodysplasia Blomstrand Type: Disease-Characteristics Report

Executive summary

Chondrodysplasia Blomstrand type—more commonly Blomstrand osteochondrodysplasia (BOCD) or Blomstrand lethal chondrodysplasia (BLC)—is an exceptionally rare, autosomal-recessive, prenatal-onset skeletal dysplasia caused by biallelic severe loss-of-function variants in PTH1R, encoding parathyroid hormone/parathyroid hormone-related peptide receptor type 1. Loss of fetal PTHrP–PTH1R signaling prematurely drives growth-plate chondrocytes from proliferation into hypertrophy and mineralization. The resulting generalized advanced ossification, shortened bones, narrow thorax, and pulmonary hypoplasia usually cause stillbirth or death minutes to hours after delivery. There is no disease-modifying treatment or validated population prevalence estimate. The strongest evidence comes from a small number of fetal case reports/series, receptor-functional studies, knockout mice, and zebrafish experiments; quantitative phenotype frequencies should therefore be interpreted cautiously. (portalescastillo2025humandiseasescaused pages 1-2, hoogendam2007novelmutationsin pages 1-2)

1. Disease information

Definition and nomenclature

BOCD is a lethal sclerosing skeletal dysplasia characterized by accelerated endochondral ossification and advanced skeletal maturation, rather than delayed mineralization. The literature uses Blomstrand osteochondrodysplasia, Blomstrand chondrodysplasia, Blomstrand lethal osteochondrodysplasia, Blomstrand lethal chondrodysplasia, and occasionally Blomstrand syndrome. Historical publications distinguish type I, with complete PTH1R inactivation and extremely short malformed bones, from the somewhat less severe but still lethal type II, associated with small amounts of residual receptor activity. (portalescastillo2025humandiseasescaused pages 8-8, portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 1-2)

Suggested identifiers—verify against the current release before database ingestion:

• OMIM: 215045, Blomstrand chondrodysplasia.
• Orphanet: commonly indexed as Blomstrand lethal chondrodysplasia; the current ORPHA numerical record should be release-validated.
• MONDO: map through the current MONDO cross-reference to OMIM:215045; a stable MONDO number was not present in the retrieved primary literature and should not be inferred from text-mining alone.
• MeSH: no clearly disease-specific MeSH descriptor was found; indexing generally falls under osteochondrodysplasias/chondrodysplasia.
• ICD-10: no dedicated code; typically falls under Q77.8, other osteochondrodysplasia with defects of growth of tubular bones and spine.
• ICD-11: use the current rare skeletal-dysplasia hierarchy; no disease-specific leaf code was verified in the retrieved evidence.

The evidence is predominantly aggregated disease-level literature derived from individually described fetuses, postmortem examinations, family segregation, and experimental models—not EHR-derived population data. Hoogendam et al. studied two type-I and three type-II families using clinical examination, imaging, histology, sequencing, RNA analysis, and receptor assays. (hoogendam2007novelmutationsin pages 1-2)

Landmark source: Hoogendam et al., published online 12 December 2006 and in March 2007, DOI: https://doi.org/10.1210/jc.2006-0300. The abstract concludes: “type I BOCD is caused by a complete inactivation of the PTHR1, whereas low levels of residual activity … result in the relatively milder presentation of type II BOCD.” (hoogendam2007novelmutationsin pages 1-2)

2. Etiology

Causal factor

The primary cause is germline biallelic PTH1R loss of function. PTH1R is a class-B G-protein-coupled receptor activated by PTH and PTHrP. In fetal growth plates, its critical ligand is PTHrP. Severe receptor loss disrupts PTHrP-dependent maintenance of proliferating chondrocytes, causing premature hypertrophic differentiation and ossification. (martin2016parathyroidhormonerelatedprotein pages 19-20, portalescastillo2025humandiseasescaused pages 1-2, portalescastillo2025humandiseasescaused pages 2-4)

Risk factors

• Genetic: two pathogenic PTH1R alleles are required for classic BOCD. Reported lesions include nonsense, frameshift, missense, and splice-altering variants. Consanguinity increases the probability that both parents carry the same rare allele, but affected offspring have also occurred in nonconsanguineous families. (hoogendam2007novelmutationsin pages 1-2)
• Family history: affected siblings and recurrent fetal losses are important clues. One Asian first-cousin couple had three similarly affected fetuses. (hoogendam2007novelmutationsin pages 1-2, hoogendam2007novelmutationsin pages 2-3)
• Sex: both male and female fetuses are reported; no sex-linked difference is established.
• Environmental, infectious, lifestyle, occupational, maternal-age, or toxicant risks: none established.

Protective factors and gene–environment interaction

No protective PTH1R allele, diet, medication, lifestyle factor, or reproducible gene–environment interaction has been reported. Because BOCD is a highly penetrant developmental receptor-null phenotype, environmental modification is not expected to prevent the skeletal lesion once an affected fetal genotype is present. This is an inference, not evidence from intervention studies.

3. Phenotypes

All manifestations are congenital/prenatal, generally severe, and nonremitting. Frequencies below are qualitative unless a study supplied a number; the literature is too small and ascertainment-biased for robust percentages.

A well-characterized 32-week fetus had polyhydramnios, a relatively large head, small thorax, lung hypoplasia, and very short dense tubular bones. Examination showed severe micrognathia, protruding tongue, narrow thorax, absent nipples, and symmetric limb shortening; imaging showed generalized osteosclerosis, advanced skeletal maturation, short ribs, ossified laryngeal cartilage and patella, metaphyseal broadening, and extensive carpal/tarsal ossification. (hoogendam2007novelmutationsin pages 2-3)

Histology demonstrated reduced epiphyses and resting/proliferative zones, near absence of columnar proliferating chondrocytes, disordered hypertrophic columns, and an irregular growth-plate–primary-spongiosa boundary. A 2023 reanalysis further identified ectopic calcified islands, disordered trabeculae, and AGGRECAN-positive ectopic chondrocytes in diaphyseal trabecular-like structures. (csukasi2023skeletaldiseasescaused pages 2-5, hoogendam2007novelmutationsin pages 2-3)

Quality of life: validated EQ-5D, SF-36, PROMIS, or disease-specific quality-of-life data do not exist. The disorder is usually incompatible with postnatal survival; family burden centers on fetal loss, reproductive decision-making, and perinatal bereavement.

4. Genetic and molecular information

• Gene: PTH1R, parathyroid hormone 1 receptor; chromosome 3p21 region; HGNC-approved symbol PTH1R.
• Protein: PTH/PTHrP receptor type 1, a seven-transmembrane class-B GPCR.
• Origin: constitutional/germline, not somatic.
• Inheritance: autosomal recessive.
• Functional class: severe or complete loss of receptor signaling. Type-II disease can retain a small amount of correctly spliced transcript or residual receptor function. (portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 1-2, hoogendam2007novelmutationsin pages 3-5)

The established severe alleles and functional interpretation are summarized below.

Table: Knowledge-base summary of five established severe PTH1R loss-of-function alleles associated with lethal Blomstrand chondrodysplasia. It records functional and phenotype evidence while flagging legacy nomenclature and uncertain review-reported frequency values.

The numeric values reproduced in the artifact from the 2025 review’s “allele frequency” field are not credible as unqualified population frequencies for a lethal recessive disorder and may reflect database formatting or very-low-frequency units. They must be checked directly in the current gnomAD/ClinVar records before knowledge-base import. Absence or extreme rarity in population databases is expected for pathogenic BOCD alleles.

The 2007 functional work showed that p.R104X eliminates essentially all receptor domains. The intronic allele created a preferred aberrant splice boundary and a truncated receptor lacking transmembrane helices 5–7 and the cytoplasmic tail, although a small amount of normal transcript remained. Patient fibroblasts failed to accumulate cAMP after high-dose PTH or PTHrP. (hoogendam2007novelmutationsin pages 3-5)

No validated modifier gene, disease-specific methylation signature, histone-mark abnormality, recurrent chromosomal rearrangement, or pathogenic copy-number syndrome has been established. DEPTOR, DVL2, TAZ, HDAC4/5, MEF2, RUNX2, SOX9, and IHH are mechanistic pathway components, not proven human BOCD modifier genes.

5. Environmental information

No toxin, radiation, pollution, occupation, smoking, alcohol, nutrition, exercise pattern, medication, infection, or microbiome exposure is known to cause or trigger BOCD. It is not contagious and has no zoonotic transmission. Environmental-factor and prophylactic-vaccine fields are therefore not applicable.

6. Mechanism and pathophysiology

Ordered causal chain

1. Biallelic severe PTH1R variants lead to absent or markedly reduced functional receptor at fetal growth-plate cells. (portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 3-5)
2. Loss of receptor function leads to failure of PTHrP-stimulated Gαs–adenylyl-cyclase–cAMP–PKA signaling; some variants also abolish phosphoinositide signaling. (guasto2021signalingpathwaysin pages 7-8, lai2008generegulationin pages 19-24)
3. Reduced PTHrP signaling leads to failure to maintain resting/proliferating chondrocytes and failure to delay hypertrophic differentiation. (martin2016parathyroidhormonerelatedprotein pages 19-20, portalescastillo2025humandiseasescaused pages 1-2)
4. Loss of this restraint leads to reduced SOX9-associated proliferative/chondrogenic activity and release of HDAC4/5–MEF2–RUNX2-mediated hypertrophic programs; the full downstream chain is demonstrated mainly in mouse growth plates and is mechanistically inferred for BOCD. (guasto2021signalingpathwaysin pages 7-8, nishimori2019pthrptargetshdac4 pages 17-17)
5. Premature chondrocyte hypertrophy leads to early cartilage mineralization, growth-plate exhaustion/disorganization, and accelerated endochondral bone formation throughout the skeleton. (portalescastillo2025humandiseasescaused pages 1-2, hoogendam2007novelmutationsin pages 2-3)
6. Growth-plate disruption leads to short malformed tubular bones, micromelia, osteosclerosis, advanced epiphyseal/carpal/tarsal/patellar ossification, and loss of normal bone–cartilage boundaries. (hoogendam2007novelmutationsin pages 2-3, csukasi2023skeletaldiseasescaused pages 2-5)
7. Accelerated rib-cage ossification and short ribs lead to a small rigid thorax, pulmonary hypoplasia, inability to ventilate, and perinatal death. (portalescastillo2025humandiseasescaused pages 1-2, hoogendam2007novelmutationsin pages 2-3)
8. Parallel branch: loss of PTHrP–PTH1R signaling during vascular development may lead to reduced local Notch signaling and endothelial loss, resulting in aortic obstruction/coarctation; this is supported by zebrafish knockdown and remains incompletely demonstrated in humans. (gray2013lossoffunction pages 5-6, gray2013lossoffunction pages 1-2)
9. Exploratory branch: PTH1R loss may dysregulate DEPTOR–DVL2–TAZ/mTOR-linked skeletal-progenitor fate, leading to ectopic chondrocytes and disordered osteogenic/chondrogenic differentiation; direct BOCD patient-cell validation is lacking. (csukasi2023skeletaldiseasescaused pages 6-8, csukasi2023skeletaldiseasescaused pages 8-9, csukasi2023skeletaldiseasescaused pages 2-5)

Pathways and cells

The normal IHH–PTHrP feedback loop spaces hypertrophic differentiation: prehypertrophic chondrocytes produce IHH, which promotes periarticular PTHrP; PTHrP then acts on PTH1R-positive proliferating/prehypertrophic chondrocytes to delay hypertrophy. Cells moving away from the PTHrP source differentiate and re-express IHH. (martin2016parathyroidhormonerelatedprotein pages 19-20, guasto2021signalingpathwaysin pages 18-19)

PTH1R can couple to Gαs/cAMP/PKA, Gαq/PLCβ/DAG/IP3/Ca²⁺, and β-arrestin pathways. Gαs signaling supports proliferation and SOX9 while suppressing hypertrophic MEF2/RUNX2 activity via nuclear HDAC4. By contrast, PLC/Ca²⁺ signaling can favor hypertrophic differentiation. BOCD-causing receptor-null variants remove the coordinated response rather than selectively increasing one branch. (guasto2021signalingpathwaysin pages 7-8, portalescastillo2025humandiseasescaused pages 1-2)

The 2023 study found absent/low DEPTOR in BOCD ectopic chondrocytes and proposed that DEPTOR interactions with PTH1R, DVL2, and TAZ regulate TAZ localization and osteogenic/adipogenic/chondrogenic fate. However, most molecular experiments used immortalized mesenchymal cells, DEPTOR knockdown, HEK293T cells, or Jansen cells; BOCD patient cells were unavailable. These results are promising pathway refinement, not a validated therapeutic target. (csukasi2023skeletaldiseasescaused pages 6-8, csukasi2023skeletaldiseasescaused pages 5-6, csukasi2023skeletaldiseasescaused pages 8-9)

Suggested GO biological-process terms: endochondral ossification (GO:0001958); cartilage development (GO:0051216); chondrocyte differentiation (GO:0002062); regulation of chondrocyte differentiation (GO:0032330); bone mineralization (GO:0030282); cAMP-mediated signaling (GO:0019933); adenylate-cyclase-activating GPCR signaling (GO:0007189); skeletal-system development (GO:0001501); blood-vessel development (GO:0001568); Notch signaling (GO:0007219).

Suggested Cell Ontology terms: chondrocyte CL:0000138; hypertrophic chondrocyte (current CL child term should be release-checked); osteoblast CL:0000062; mesenchymal stem cell CL:0000134; vascular endothelial cell CL:0000115.

Subcellular components: plasma membrane (GO:0005886), receptor complex (GO:0043235), cytoplasm (GO:0005737), nucleus (GO:0005634). There is no evidence that BOCD is primarily mitochondrial, lysosomal, ER-storage, inflammatory, autoimmune, or metabolic.

7. Anatomical structures affected

Primary: appendicular and axial skeleton, fetal growth plates, epiphyseal cartilage, ribs, craniofacial skeleton, laryngeal cartilage, carpal/tarsal elements, patellae, and developing teeth. Suggested UBERON mappings include growth plate cartilage UBERON:0004766, cartilage tissue UBERON:0002418, bone tissue UBERON:0002481, rib UBERON:0002228, lung UBERON:0002048, mandible UBERON:0001684, and aorta UBERON:0000947.

Secondary: lungs are hypoplastic because of thoracic restriction; the aorta may show preductal coarctation; mammary glands/nipples may be absent; congenital cataracts are occasional. (portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 2-3)

The skeletal involvement is generalized and usually symmetric; no consistent lateralization is described.

8. Temporal development

• Onset: embryonic/fetal, during endochondral skeletal development.
• Prenatal recognition: possible in the first trimester in recurrent families and later through ultrasound evidence of short dense bones, small thorax, and polyhydramnios; historical literature contains a first-trimester diagnosis report. (portalescastillo2025humandiseasescaused pages 8-8)
• Course: continuously developmental rather than episodic or relapsing. Ossification becomes excessively advanced with gestation.
• End stage: miscarriage, termination after prenatal diagnosis, stillbirth, or death shortly after delivery from respiratory failure/pulmonary hypoplasia.
• Remission/recovery: none known.
• Critical period: early fetal growth-plate development. Intervention after severe thoracic and pulmonary maldevelopment would be unlikely to reverse anatomy; no prenatal molecular therapy has been tested.

9. Inheritance and population

BOCD is autosomal recessive. If both parents carry pathogenic alleles in the same gene, each pregnancy has the conventional Mendelian probabilities of 25% affected, 50% carrier, and 25% unaffected/noncarrier, assuming confirmed parental carrier status and no unusual allele behavior.

Penetrance of severe biallelic null genotypes appears high, but a formal penetrance estimate is impossible. Expressivity varies with residual receptor function: complete inactivation is associated with type I, whereas hypomorphic alleles can produce type II. Much milder biallelic PTH1R phenotypes—Eiken syndrome, PTH resistance, and tooth-eruption failure—show that genotype–phenotype prediction must incorporate functional severity rather than merely “biallelic versus monoallelic.” (portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 7-8, hoogendam2007novelmutationsin pages 1-2)

No anticipation, established germline-mosaicism series, founder effect, carrier frequency, ethnic enrichment, geographic endemicity, incidence, or prevalence per 100,000 has been established. Cases include European/Caucasian, Asian, and Turkish families and both sexes. Published case numbers remain only in the low tens; this is a literature impression, not a registry-derived statistic. Consanguinity is recurrent but not obligatory. (hoogendam2007novelmutationsin pages 1-2)

10. Diagnostics

Clinical and prenatal approach

1. Detailed fetal ultrasound: assess long-bone length and density, thoracic size, ribs, craniofacial proportions, lungs, polyhydramnios, edema/hydrops, and associated cardiac anatomy.
2. Fetal radiography or low-dose CT where clinically justified: demonstrates generalized osteosclerosis and markedly advanced ossification, including unusually early carpal, tarsal, patellar, and laryngeal-cartilage mineralization.
3. Fetal echocardiography: evaluate the aortic arch because coarctation is reported.
4. Molecular confirmation: sequence PTH1R and perform deletion/duplication analysis if sequencing is negative. Parental testing establishes phase and recurrence risk.
5. Postmortem examination: skeletal survey, lung and cardiovascular examination, and growth-plate histology are valuable for definitive diagnosis and counseling.

The primary series explicitly combined “clinical, radiographical, histological, and biochemical” criteria with PTH1R analysis. (hoogendam2007novelmutationsin pages 1-2, hoogendam2007novelmutationsin pages 2-3)

Genetic-test selection

• Known familial variant: targeted testing by chorionic-villus sampling or amniocentesis is preferred.
• Strong BOCD phenotype: single-gene PTH1R testing or a lethal skeletal-dysplasia panel with copy-number analysis.
• Uncertain skeletal dysplasia: trio WES/WGS can identify PTH1R and phenocopies. WGS is useful for deep-intronic/structural lesions; a 2007 type-I case had no coding or splice-boundary variant detected, illustrating that standard exon sequencing can miss a causal lesion. (hoogendam2007novelmutationsin pages 1-2, hoogendam2007novelmutationsin pages 3-5)
• CMA/karyotype: useful for a broader fetal-anomaly differential, but not the primary assay for this single-gene disorder.
• FISH, mitochondrial testing, repeat-expansion testing, RNA-omics, proteomics, metabolomics, epigenomics, and liquid biopsy: not routine BOCD tests.
• RNA studies: useful when a splice variant is suspected; RT-PCR demonstrated preferential aberrant splicing and residual normal transcript for intron M4+27C>T. (hoogendam2007novelmutationsin pages 7-8, hoogendam2007novelmutationsin pages 3-5)

Differential diagnosis

Important alternatives include other lethal skeletal dysplasias—thanatophoric dysplasia, achondrogenesis, osteogenesis imperfecta type II, hypophosphatasia, short-rib thoracic dysplasias, campomelic dysplasia, and perinatal hypophosphatasia. Advanced generalized ossification/osteosclerosis, premature patellar/carpal/tarsal/laryngeal ossification, reduced growth-plate proliferation, and biallelic PTH1R loss distinguish BOCD. PTH1R-related differentials include Eiken syndrome, which has delayed rather than accelerated ossification; activating-PTH1R Jansen metaphyseal chondrodysplasia; and heterozygous PTH1R-associated primary failure of tooth eruption. (hoogendam2007novelmutationsin pages 1-2, risom2013identificationofsix pages 7-7, portalescastillo2025humandiseasescaused pages 2-4)

There are no consensus society diagnostic criteria, newborn screening, biochemical screening biomarker, or validated prenatal risk calculator.

11. Outcome and prognosis

Prognosis is uniformly grave for classic BOCD. A 32-week infant did not breathe and died within minutes; autopsy showed pulmonary hypoplasia and preductal aortic coarctation. The literature’s first described infant was delivered at 22 weeks and died shortly afterward. (portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 2-3)

No five- or ten-year survival statistics exist because classic disease is prenatal/perinatal lethal. The proximate mechanism is restrictive thoracic maldevelopment and lung hypoplasia; cardiovascular abnormalities may add risk. Type II is radiographically less severe but remains lethal. No validated prognostic biomarker exists beyond genotype/function and the severity of thoracic/pulmonary involvement. (portalescastillo2025humandiseasescaused pages 1-2, hoogendam2007novelmutationsin pages 1-2)

12. Treatment

No approved pharmacotherapy, gene therapy, cell therapy, RNA therapy, surgery, or disease-modifying prenatal intervention exists. A search of ClinicalTrials.gov retrieved no relevant BOCD-specific interventional trial or NCT identifier.

Management is therefore:

• multidisciplinary prenatal diagnosis and counseling;
• fetal echocardiographic and obstetric assessment;
• discussion of pregnancy options according to local law and family values;
• delivery planning that avoids futile traumatic intervention where lethality is certain;
• neonatal comfort care/palliative respiratory support when appropriate;
• autopsy/tissue preservation and molecular confirmation;
• psychological and bereavement support.

Suggested NCIT intervention concepts include Genetic Counseling, Prenatal Genetic Testing, Palliative Care, Supportive Care, and Whole Exome Sequencing; exact NCIT codes should be mapped in the current release.

PTH or PTHrP replacement is not an established therapy: severe receptor-null disease cannot be corrected simply by supplying more ligand. Experimental PTH1R inverse agonists developed for activating Jansen disease address the opposite signaling defect and are not applicable to BOCD. The 2023 DEPTOR–TAZ findings remain preclinical and do not constitute a treatment. (csukasi2023skeletaldiseasescaused pages 6-8, csukasi2023skeletaldiseasescaused pages 8-9)

13. Prevention

• Primary prevention: no lifestyle or environmental prevention is possible.
• Reproductive prevention/choice: carrier testing for relatives after identification of the familial alleles; preimplantation genetic testing for monogenic disease; targeted prenatal diagnosis by CVS or amniocentesis; early expert ultrasound.
• Secondary prevention: early fetal diagnosis prevents diagnostic uncertainty and permits informed pregnancy and delivery planning, but does not prevent disease progression.
• Tertiary prevention: comfort-focused perinatal care can reduce suffering; there is no way to prevent the lethal skeletal/pulmonary complication after it is established.
• Immunization, public-health sanitation, exposure reduction, and medication prophylaxis: not applicable.

14. Other species and natural disease

No well-established naturally occurring veterinary counterpart or breed predisposition was identified. Therefore, OMIA/VBO breed mapping and veterinary prevalence cannot presently be supplied. PTH1R signaling is evolutionarily conserved across vertebrates, but experimental phenocopies should not be labeled naturally occurring disease. There is no zoonotic potential or cross-species transmission.

15. Model organisms and experimental systems

Mouse

Pth1r-null and Pthlh/PTHrP-null mice die neonatally and show shortened bones, abbreviated proliferative zones, disrupted growth-plate organization, premature hypertrophy and accelerated ossification, closely phenocopying human BOCD. Transgenic PTHrP expression in proliferating chondrocytes partially rescues Pthlh-null lethality, establishing tissue-specific pathway causality. Limitations include species-specific anatomy and the absence of human allelic heterogeneity. (martin2016parathyroidhormonerelatedprotein pages 19-20, portalescastillo2025humandiseasescaused pages 1-2, portalescastillo2025humandiseasescaused pages 2-4)

Zebrafish

Morpholino knockdown of either pthr1 or pthrp caused a localized mid-aortic occlusion from endothelial loss, preceded by defective hypochordal Notch signaling; inducible Notch upregulation rescued the lesion. The abstract states: “Loss of function of either PTHR1 or PTHrP leads to a localized aortic defect that is Notch dependent.” This supports, but does not prove, a direct mechanism for human BOCD-associated coarctation. Morpholino partial knockdown and differences between fish aortic occlusion and human coarctation are major limitations. Gray et al., June 2013, DOI: https://doi.org/10.1161/ATVBAHA.112.300590. (gray2013lossoffunction pages 5-6, gray2013lossoffunction pages 1-2)

Human tissue and cellular systems

Patient fetal growth plates provide the most disease-proximal pathology evidence. Patient dermal fibroblasts and transfected COS-7 cells established loss of PTH/PTHrP-induced cAMP signaling and residual activity for hypomorphic variants. These cells are useful for receptor pharmacology but do not fully reproduce growth-plate differentiation. (hoogendam2007novelmutationsin pages 2-3, hoogendam2007novelmutationsin pages 3-5)

The 2023 DEPTOR study used BOCD tissue, immortalized mesenchymal stem cells, HEK293T interaction assays, and Jansen fibroblasts. It linked DEPTOR–DVL2–TAZ to skeletal lineage choice, but lacked BOCD patient-derived progenitor cells and direct rescue of the lethal phenotype. Csukasi et al., January 2023, DOI: https://doi.org/10.3389/fcell.2022.963389. (csukasi2023skeletaldiseasescaused pages 6-8, csukasi2023skeletaldiseasescaused pages 5-6, csukasi2023skeletaldiseasescaused pages 8-9)

No validated BOCD iPSC, organoid, single-cell atlas, spatial-transcriptomic dataset, CRISPR screen, or integrated disease-specific proteomic/metabolomic/lipidomic signature was identified.

Recent developments, 2023–2024, and expert assessment

The most disease-relevant 2023 advance was the identification of abnormal BOCD skeletal-progenitor patterning and low DEPTOR in ectopic chondrocytes, with a proposed DEPTOR–DVL2–TAZ mechanism. It expands BOCD biology beyond a simple “premature hypertrophy” model, but remains partly extrapolative because BOCD living cells were unavailable. (csukasi2023skeletaldiseasescaused pages 6-8, csukasi2023skeletaldiseasescaused pages 2-5, csukasi2023skeletaldiseasescaused pages 1-2)

A 2024 PTH1R family study concerned a heterozygous allele and incomplete penetrance in a broader PTH1R phenotype, not classic recessive lethal BOCD. Its relevance is chiefly interpretive: PTH1R variant effect, zygosity, receptor domain, and residual signaling—not gene name alone—determine phenotype. No 2023–2024 BOCD therapeutic trial, epidemiologic cohort, single-cell study, or survival improvement was identified.

The current expert view is consequently stable: classic BOCD is a receptor-loss developmental disorder in which complete PTH1R inactivation produces type-I disease, while residual activity can soften skeletal morphology to type II without reliably restoring viability. Recent mechanistic work refines downstream lineage biology, but diagnosis and family planning—not treatment—remain the principal real-world applications. (csukasi2023skeletaldiseasescaused pages 8-9, portalescastillo2025humandiseasescaused pages 2-4, hoogendam2007novelmutationsin pages 1-2)

Evidence limitations

The evidence base comprises very few fetuses, heterogeneous historical reports, postmortem ascertainment, and model systems. Apparent frequencies—including the approximately 50% estimate for aortic coarctation—must not be treated as population estimates. There are no registries large enough to establish incidence, penetrance, sex ratio, carrier frequency, survival curves, quality-of-life scores, or treatment-response rates. Primary-study PMIDs were not consistently present in the retrieved full texts; DOI URLs have therefore been supplied rather than inventing unverified PMID mappings.

References

1. (portalescastillo2025humandiseasescaused pages 1-2): Ignacio Portales-Castillo, Jakob Höppner, Harald Jüppner, and Thomas J. Gardella. Human diseases caused by homozygous pth1r mutations. Frontiers in Endocrinology, Aug 2025. URL: https://doi.org/10.3389/fendo.2025.1641292, doi:10.3389/fendo.2025.1641292. This article has 4 citations.

2. (hoogendam2007novelmutationsin pages 1-2): J. Hoogendam, H. Farih‐Sips, L. C. Wÿnaendts, Clemens W.G.M. Löwik, J. Wit, and Marcel Karperien. Novel mutations in the parathyroid hormone (pth)/pth-related peptide receptor type 1 causing blomstrand osteochondrodysplasia types i and ii. The Journal of clinical endocrinology and metabolism, 92 3:1088-95, Mar 2007. URL: https://doi.org/10.1210/jc.2006-0300, doi:10.1210/jc.2006-0300. This article has 62 citations.

3. (portalescastillo2025humandiseasescaused pages 8-8): Ignacio Portales-Castillo, Jakob Höppner, Harald Jüppner, and Thomas J. Gardella. Human diseases caused by homozygous pth1r mutations. Frontiers in Endocrinology, Aug 2025. URL: https://doi.org/10.3389/fendo.2025.1641292, doi:10.3389/fendo.2025.1641292. This article has 4 citations.

4. (portalescastillo2025humandiseasescaused pages 2-4): Ignacio Portales-Castillo, Jakob Höppner, Harald Jüppner, and Thomas J. Gardella. Human diseases caused by homozygous pth1r mutations. Frontiers in Endocrinology, Aug 2025. URL: https://doi.org/10.3389/fendo.2025.1641292, doi:10.3389/fendo.2025.1641292. This article has 4 citations.

5. (martin2016parathyroidhormonerelatedprotein pages 19-20): T. John Martin. Parathyroid hormone-related protein, its regulation of cartilage and bone development, and role in treating bone diseases. Physiological reviews, 96 3:831-71, Jul 2016. URL: https://doi.org/10.1152/physrev.00031.2015, doi:10.1152/physrev.00031.2015. This article has 203 citations and is from a highest quality peer-reviewed journal.

6. (hoogendam2007novelmutationsin pages 2-3): J. Hoogendam, H. Farih‐Sips, L. C. Wÿnaendts, Clemens W.G.M. Löwik, J. Wit, and Marcel Karperien. Novel mutations in the parathyroid hormone (pth)/pth-related peptide receptor type 1 causing blomstrand osteochondrodysplasia types i and ii. The Journal of clinical endocrinology and metabolism, 92 3:1088-95, Mar 2007. URL: https://doi.org/10.1210/jc.2006-0300, doi:10.1210/jc.2006-0300. This article has 62 citations.

7. (csukasi2023skeletaldiseasescaused pages 2-5): Fabiana Csukasi, Michaela Bosakova, Tomas Barta, Jorge H. Martin, Jesus Arcedo, Maya Barad, Gustavo A. Rico-Llanos, Jennifer Zieba, Jose Becerra, Pavel Krejci, Ivan Duran, and Deborah Krakow. Skeletal diseases caused by mutations in pth1r show aberrant differentiation of skeletal progenitors due to dysregulation of deptor. Frontiers in Cell and Developmental Biology, Jan 2023. URL: https://doi.org/10.3389/fcell.2022.963389, doi:10.3389/fcell.2022.963389. This article has 5 citations.

8. (hoogendam2007novelmutationsin pages 3-5): J. Hoogendam, H. Farih‐Sips, L. C. Wÿnaendts, Clemens W.G.M. Löwik, J. Wit, and Marcel Karperien. Novel mutations in the parathyroid hormone (pth)/pth-related peptide receptor type 1 causing blomstrand osteochondrodysplasia types i and ii. The Journal of clinical endocrinology and metabolism, 92 3:1088-95, Mar 2007. URL: https://doi.org/10.1210/jc.2006-0300, doi:10.1210/jc.2006-0300. This article has 62 citations.

9. (hoogendam2007novelmutationsin pages 7-8): J. Hoogendam, H. Farih‐Sips, L. C. Wÿnaendts, Clemens W.G.M. Löwik, J. Wit, and Marcel Karperien. Novel mutations in the parathyroid hormone (pth)/pth-related peptide receptor type 1 causing blomstrand osteochondrodysplasia types i and ii. The Journal of clinical endocrinology and metabolism, 92 3:1088-95, Mar 2007. URL: https://doi.org/10.1210/jc.2006-0300, doi:10.1210/jc.2006-0300. This article has 62 citations.

10. (risom2013identificationofsix pages 7-7): Lotte Risom, Line Christoffersen, Jette Daugaard-Jensen, Hanne Dahlgaard Hove, Henriette Skovgaard Andersen, Brage Storstein Andresen, Sven Kreiborg, and Morten Duno. Identification of six novel pth1r mutations in families with a history of primary failure of tooth eruption. PLoS ONE, 8:e74601, Sep 2013. URL: https://doi.org/10.1371/journal.pone.0074601, doi:10.1371/journal.pone.0074601. This article has 76 citations and is from a peer-reviewed journal.

11. (guasto2021signalingpathwaysin pages 7-8): Alessandra Guasto and Valérie Cormier-Daire. Signaling pathways in bone development and their related skeletal dysplasia. International Journal of Molecular Sciences, 22:4321, Apr 2021. URL: https://doi.org/10.3390/ijms22094321, doi:10.3390/ijms22094321. This article has 106 citations.

12. (lai2008generegulationin pages 19-24): LP Lai. Gene regulation in growth plate chondrocytes by the parathyroid hormone 1 receptor and the beta2-adrenergic receptor. Unknown journal, 2008.

13. (nishimori2019pthrptargetshdac4 pages 17-17): Shigeki Nishimori, Forest Lai, Mieno Shiraishi, Tatsuya Kobayashi, Elena Kozhemyakina, Tso-Pang Yao, Andrew B. Lassar, and Henry M. Kronenberg. Pthrp targets hdac4 and hdac5 to repress chondrocyte hypertrophy. JCI insight, Mar 2019. URL: https://doi.org/10.1172/jci.insight.97903, doi:10.1172/jci.insight.97903. This article has 64 citations and is from a domain leading peer-reviewed journal.

14. (gray2013lossoffunction pages 5-6): Caroline Gray, David Bratt, Julie Lees, Marc daCosta, Karen Plant, Oliver J. Watson, Sara Solaymani-Kohal, Simon Tazzyman, Jovana Serbanovic-Canic, David C. Crossman, Bernard D. Keavney, Andrea Haase, Kathryn McMahon, Martin Gering, Henry Roehl, Paul C. Evans, and Timothy J.A. Chico. Loss of function of parathyroid hormone receptor 1 induces notch-dependent aortic defects during zebrafish vascular development. Arteriosclerosis, Thrombosis, and Vascular Biology, 33:1257–1263, Jun 2013. URL: https://doi.org/10.1161/atvbaha.112.300590, doi:10.1161/atvbaha.112.300590. This article has 16 citations and is from a domain leading peer-reviewed journal.

15. (gray2013lossoffunction pages 1-2): Caroline Gray, David Bratt, Julie Lees, Marc daCosta, Karen Plant, Oliver J. Watson, Sara Solaymani-Kohal, Simon Tazzyman, Jovana Serbanovic-Canic, David C. Crossman, Bernard D. Keavney, Andrea Haase, Kathryn McMahon, Martin Gering, Henry Roehl, Paul C. Evans, and Timothy J.A. Chico. Loss of function of parathyroid hormone receptor 1 induces notch-dependent aortic defects during zebrafish vascular development. Arteriosclerosis, Thrombosis, and Vascular Biology, 33:1257–1263, Jun 2013. URL: https://doi.org/10.1161/atvbaha.112.300590, doi:10.1161/atvbaha.112.300590. This article has 16 citations and is from a domain leading peer-reviewed journal.

16. (csukasi2023skeletaldiseasescaused pages 6-8): Fabiana Csukasi, Michaela Bosakova, Tomas Barta, Jorge H. Martin, Jesus Arcedo, Maya Barad, Gustavo A. Rico-Llanos, Jennifer Zieba, Jose Becerra, Pavel Krejci, Ivan Duran, and Deborah Krakow. Skeletal diseases caused by mutations in pth1r show aberrant differentiation of skeletal progenitors due to dysregulation of deptor. Frontiers in Cell and Developmental Biology, Jan 2023. URL: https://doi.org/10.3389/fcell.2022.963389, doi:10.3389/fcell.2022.963389. This article has 5 citations.

17. (csukasi2023skeletaldiseasescaused pages 8-9): Fabiana Csukasi, Michaela Bosakova, Tomas Barta, Jorge H. Martin, Jesus Arcedo, Maya Barad, Gustavo A. Rico-Llanos, Jennifer Zieba, Jose Becerra, Pavel Krejci, Ivan Duran, and Deborah Krakow. Skeletal diseases caused by mutations in pth1r show aberrant differentiation of skeletal progenitors due to dysregulation of deptor. Frontiers in Cell and Developmental Biology, Jan 2023. URL: https://doi.org/10.3389/fcell.2022.963389, doi:10.3389/fcell.2022.963389. This article has 5 citations.

18. (guasto2021signalingpathwaysin pages 18-19): Alessandra Guasto and Valérie Cormier-Daire. Signaling pathways in bone development and their related skeletal dysplasia. International Journal of Molecular Sciences, 22:4321, Apr 2021. URL: https://doi.org/10.3390/ijms22094321, doi:10.3390/ijms22094321. This article has 106 citations.

19. (csukasi2023skeletaldiseasescaused pages 5-6): Fabiana Csukasi, Michaela Bosakova, Tomas Barta, Jorge H. Martin, Jesus Arcedo, Maya Barad, Gustavo A. Rico-Llanos, Jennifer Zieba, Jose Becerra, Pavel Krejci, Ivan Duran, and Deborah Krakow. Skeletal diseases caused by mutations in pth1r show aberrant differentiation of skeletal progenitors due to dysregulation of deptor. Frontiers in Cell and Developmental Biology, Jan 2023. URL: https://doi.org/10.3389/fcell.2022.963389, doi:10.3389/fcell.2022.963389. This article has 5 citations.

20. (csukasi2023skeletaldiseasescaused pages 1-2): Fabiana Csukasi, Michaela Bosakova, Tomas Barta, Jorge H. Martin, Jesus Arcedo, Maya Barad, Gustavo A. Rico-Llanos, Jennifer Zieba, Jose Becerra, Pavel Krejci, Ivan Duran, and Deborah Krakow. Skeletal diseases caused by mutations in pth1r show aberrant differentiation of skeletal progenitors due to dysregulation of deptor. Frontiers in Cell and Developmental Biology, Jan 2023. URL: https://doi.org/10.3389/fcell.2022.963389, doi:10.3389/fcell.2022.963389. This article has 5 citations.

Artifacts

• Edison artifact artifact-00

Reference Validation

Checked with linkml-reference-validator 0.2.1.

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Unresolved terms

These identifiers do not exist in an ontology that resolved other terms from the same prefix, so they were most likely invented:

• HP:0002796 (1 mention) - HP does not contain this term

Obsolete terms

These terms are real but deprecated. Citing one is not a fabrication; it does mean the report is naming something the ontology has retired:

• GO:0019933 (obsolete cAMP-mediated signaling) (1 mention)

Prefixes with no resolver

Terms carrying these prefixes were not checked either way, because no configured ontology covers them. An unrecognised prefix may name an ontology this run could not reach as easily as one that does not exist, so nothing here is evidence of fabrication: OMIM.